Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Drug Therapy for Behavioral and Psychological Symptoms of Dementia.

Wang F, Feng TY, Yang S, Preter M, Zhou JN, Wang XP.

Curr Neuropharmacol. 2016;14(4):307-13.

PMID:
26644152
2.

Assessment and management of behavioral and psychological symptoms of dementia.

Kales HC, Gitlin LN, Lyketsos CG.

BMJ. 2015 Mar 2;350:h369. doi: 10.1136/bmj.h369. Review.

3.

The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.

Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, Martin JJ, De Deyn PP.

Alzheimers Res Ther. 2015 Feb 11;7(1):7. doi: 10.1186/s13195-014-0090-1. eCollection 2015.

4.

Pharmacological management of behavioral symptoms associated with dementia.

Madhusoodanan S, Ting MB.

World J Psychiatry. 2014 Dec 22;4(4):72-9. doi: 10.5498/wjp.v4.i4.72. Review.

5.

Role of citalopram in the treatment of agitation in Alzheimer's disease.

Porsteinsson AP, Keltz MA, Smith JS.

Neurodegener Dis Manag. 2014;4(5):345-9. doi: 10.2217/nmt.14.35.

6.

Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

Herrmann N, Lanctôt KL, Hogan DB.

Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S5. doi: 10.1186/alzrt201. Epub 2013 Jul 8.

7.

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group.

JAMA. 2014 Feb 19;311(7):682-91. doi: 10.1001/jama.2014.93.

8.

Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer's Disease.

Benhabib H, Lanctôt KL, Eryavec GM, Li A, Herrmann N.

Can Geriatr J. 2013 Dec 3;16(4):180-5. doi: 10.5770/cgj.16.78. eCollection 2013.

9.

Sertraline effects on cerebrospinal fluid monoamines and species-typical socioemotional behavior of female cynomolgus monkeys.

Shively CA, Register TC, Higley JD, Willard SL.

Psychopharmacology (Berl). 2014 Apr;231(7):1409-16. doi: 10.1007/s00213-013-3329-9. Epub 2013 Nov 6.

10.

Psychosis in Alzheimer's disease.

Murray PS, Kumar S, Demichele-Sweet MA, Sweet RA.

Biol Psychiatry. 2014 Apr 1;75(7):542-52. doi: 10.1016/j.biopsych.2013.08.020. Epub 2013 Oct 6. Review.

11.

The threat of behavioral changes in dementia.

Burke AD, Yaari R, Tariot PN, Hall GR, Dougherty J, Brand H, Fleisher AS.

Prim Care Companion CNS Disord. 2013;15(1). pii: PCC.13alz01507. doi: 10.4088/PCC.13alz01507. Epub 2013 Feb 28. No abstract available.

12.

Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units.

Gustafsson M, Karlsson S, Lövheim H.

BMC Pharmacol Toxicol. 2013 Feb 8;14:10. doi: 10.1186/2050-6511-14-10.

13.

A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.

Ismail Z, Emeremni CA, Houck PR, Mazumdar S, Rosen J, Rajji TK, Pollock BG, Mulsant BH.

Am J Geriatr Psychiatry. 2013 Jan;21(1):78-87. doi: 10.1016/j.jagp.2012.10.013. Epub 2013 Jan 2.

14.

Psychotropic medication use in canadian long-term care patients referred for psychogeriatric consultation.

Fischer CE, Cohen C, Forrest L, Schweizer TA, Wasylenki D.

Can Geriatr J. 2011 Sep;14(3):73-7. doi: 10.5770/cgj.v14i3.18. Epub 2011 Nov 11.

15.

Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review.

Seitz DP, Gill SS, Herrmann N, Brisbin S, Rapoport MJ, Rines J, Wilson K, Le Clair K, Conn DK.

Int Psychogeriatr. 2013 Feb;25(2):185-203. doi: 10.1017/S1041610212001627. Epub 2012 Oct 19. Review.

16.

Treatment outcomes of a crisis intervention program for dementia with severe psychiatric complications: the Kansas bridge project.

Johnson DK, Niedens M, Wilson JR, Swartzendruber L, Yeager A, Jones K.

Gerontologist. 2013 Feb;53(1):102-12. doi: 10.1093/geront/gns104. Epub 2012 Aug 30.

17.

Citalopram for agitation in Alzheimer's disease: design and methods.

Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, Pollock BG, Lyketsos CG; CitAD Research Group.

Alzheimers Dement. 2012;8(2):121-30. doi: 10.1016/j.jalz.2011.01.007. Epub 2012 Feb 1.

18.

Alzheimer's disease: diagnosis and treatment across the spectrum of disease severity.

Neugroschl J, Wang S.

Mt Sinai J Med. 2011 Jul-Aug;78(4):596-612. doi: 10.1002/msj.20279. Review.

19.

Between Scylla and Charybdis: antipsychotic and other psychotropic medications in older nursing home residents.

Pollock BG, Mulsant BH.

CMAJ. 2011 Apr 19;183(7):778-9. doi: 10.1503/cmaj.110348. Epub 2011 Mar 28. No abstract available.

20.

The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.

Devanand DP, Mintzer J, Schultz S, Sultzer D, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Andrews H, Levin B.

Am J Geriatr Psychiatry. 2012 Apr;20(4):362-73. doi: 10.1097/JGP.0b013e3182110563.

Items per page

Supplemental Content

Write to the Help Desk